Return On Equity
-48%
Metric score 0.0/100
- Info
- Insider Trading
- Financials
- Holders
Atara Biotherapeutics, Inc. financial metrics
Professional SEC-based dashboard for profitability, financial health, and growth with transparent scoring logic. Latest period: Q1 2026.
- Symbol
- ATRA on Nasdaq
- Location
- Thousand Oaks, CA
- Fiscal year end
- 31 December
- Latest financial report
- 16 Mar 2026
Latest SEC snapshot (2026-03-10) highlights Return On Equity -48.1%, Return On Assets 30.9%, and Operating Margin -102.7%.
How Calculated (standard_v1)
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
- TTM Operating Income / TTM Revenues
- Current Assets / Current Liabilities (latest instant quarter)
- (Current Assets - Inventory) / Current Liabilities; fallback: (Cash+Short-Term Investments + Accounts Receivable) / Current Liabilities
- Total Debt / Stockholders Equity (latest instant quarter; shared unit; freshest series)
- TTM Net Income / Average Equity (current quarter + same quarter previous year) / 2
- TTM Net Income / Average Assets (current quarter + same quarter previous year) / 2
- TTM NOPAT / Average Invested Capital, where NOPAT=Operating Income*(1-tax rate), Invested Capital=Equity+Total Debt-Cash & ST Investments
- TTM Revenues YoY
- TTM Net Income YoY
Financial Quality Score
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
51.5/100
Caution Confidence high
Return On Assets
31%
Metric score 100.0/100
Financial Health
- Current Ratio
- 1.02x
- Quick Ratio
- 0.86x
- Debt to Equity
- -1.9x
Strengths
Return On Assets, Current Ratio, and Quick Ratio
Watchpoints
Return On Equity, Operating Margin, and Debt-to-equity
Key metrics snapshot
Return On Equity
-48%
YoY: -99%
Industry median: -47% (n=217)
Return On Assets
31%
YoY: -181%
Industry median: -45% (n=216)
Operating Margin
-103%
YoY: -146%
Industry median: -314% (n=94)
Current Ratio
1.02x
YoY: +70%
Industry median: 3.67x (n=218)
Quick Ratio
0.86x
YoY: +231%
Industry median: 2.63x (n=83)
Debt-to-equity
-1.9x
YoY: -19%
Industry median: 0.28x (n=202)
Revenues YoY
-6.3%
YoY:
Industry median: 17% (n=40)
NetIncomeLoss YoY
73%
YoY:
Industry median: -9.9% (n=211)
Profitability
| Metric | Latest value | YoY change |
|---|---|---|
| Return On Equity | -48% | -99% |
| Return On Assets | 31% | -181% |
| Operating Margin | -103% | -146% |
Financial Health
| Metric | Latest value | YoY change |
|---|---|---|
| Current Ratio | 1.02x | +70% |
| Quick Ratio | 0.86x | +231% |
| Debt-to-equity | -1.9x | -19% |
Growth
| Metric | Latest value | YoY change |
|---|---|---|
| Revenues YoY | -6.3% | |
| NetIncomeLoss YoY | 73% |
Share Metrics
| Metric | Latest value | YoY change |
|---|---|---|
| Entity Common Stock, Shares Outstanding | 8,178,114 | +40% |
How we score
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |